Author/Editor		Kranjec, Igor
Title		Perkutani koronarni revaskularizacijski posegi in antiagregacijsko zdravljenje - vodenje v ambulantah ZDM
Translated title		Percutaneous coronary revascularization techniques and antiaggregational treatment - management in general practice
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 40, št. Suppl 1
Publication year		2001
Volume		str. 131-6
Language		slo
Abstract		Percutaneous coronary interventions (PCI) improve a diseased coronary artery lumen by causing extensive damage on the blood vessel wall. 'The consequential platelet adhesion and aggregation may lead to thrombotic occlusion of a dilated coronary artery. Aggressive antiplatelet treatment using aspirin and clopidogrel or ticlopiditne is effective against ischemic complications following PCI. Aspirin treatment should be life-long in patients with obstructive coronary artery disease; clopidogrel or ticlopidine is, on the other hand; only needed for a month after stent deployment. A combination of aspirin and clopidogrel is quite safe; however, ticlopidine may cause serious side effects including harmful neutropenia. WBC count should be therefore repeated in the second and fourth weeks of ticlopidine therapy.
Summary		Perkutana koronarna revaskularizacija (PKR) povzroči obsežno poškodbo koronarne žilne stene. V celjenju te poškodbe je v ospredju živahno trombocitno dogajanje, ki vodi v nastanek trombocitnih strdkov in kasneje v potencialno zaporo dilatirane koronarne arterije. Agresivno antiagregacijsko zdravljenje s kombinacijo aspirina in klopidogrela ali tiklopidina uspešno prepreči ishemične zaplete po PCI. Zdravljenje z aspirinom naj bo pri bolnikih po PKR doživljenjsko, klopidogrel ali tiklopidin pa naj prejemajo še mesec dni po vstavitvi žilne opornice. Kombinacija aspirina in klopidogrela povzročile malo neželenih učinkov, pri tiklopidinu pa moramo paziti zlasti na nevarno nevtropenijo. Kontrala bele krvne slike je zato nujna drugi in četrti teden zdravljenja.
Descriptors		ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY PLATELET AGGREGATION INHIBITORS CORONARY ARTERIOSCLEROSIS